| 标题 |
Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage |
| 网址 | |
| DOI | |
| 其它 |
期刊:Mol Ther 作者:Satrusal SR, Banerjee A, Biswas A, Srivastava G, Chatterjee I, Khan MA, Mandal B, Tripathi K, Sinha A, Verma A, Rai P, Akbar M, Kumar S, Chatterjee S, Singh K, Nazir A, Bhatta RS, Panda G, Datta D 出版日期:2026-08-25 |
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |
PDF的下载单位、IP信息已删除
(2025-6-4)